CareSource

MEDICAL POLICY STATEMENT
Georgia Medicaid

Policy Name & Number	Date Effective
Peripheral Nerve Blocks for Treatment of Pain-GA MCD-MM-1432	11/01/2026
Policy Type	
MEDICAL	

Medical Policy Statements are developed from a review of the available evidence-based, clinical information based on and supported by clinical guidelines from medical specialties, peer-reviewed medical and scientific studies, nationally recognized utilization and technology assessment guidelines, and other medical management industry standards to aid in determining the medical necessity of a service. Medically necessary services are defined in the plan-specific Evidence of Coverage, Member Handbooks, Provider Manuals, Medical Policy Statements, and/or other plan policies and procedures.

Medical Policy Statements do not guarantee an authorization or payment of services. Please refer to the plan contract (e.g., Evidence of Coverage, Member Handbook) for the service(s) referenced in the Medical Policy Statement. Except as otherwise required by law, if there is a conflict between the Medical Policy Statement and the plan contract and/or provider agreement, then the plan contract and/or provider agreement will be the controlling document. Reasonable discretion may be used in interpreting and applying this Policy Statement to services provided in a particular case, and the policy may be modified at any time. Medical Policy Statements may be superseded by federal and state laws and regulations, as applicable. In the case of a discrepancy between the Policy Statement's effective date and any applicable legal or regulatory requirement, the law or regulation will govern.

Coverage for mental health and substance use disorder (MH/SUD) benefits are provided at the same level as coverage for medical and surgical (M/S) benefits, as required by the Mental Health Parity and Addiction Equity Act (MHPAEA). MH/SUD benefits are not subject to limits or requirements that are more restrictive than those that apply to M/S benefits.

Table of Contents

A. Subject 2
B. Background 2
C. Definitions 2
D. Policy 3
E. Conditions of Coverage 4
F. Related Policies/Rules 4
G. Review/Revision History 5
H. References 5

A. Subject

Peripheral Nerve Blocks for Treatment of Pain

B. Background

Peripheral nerve blocks are injections of medication into a specific area of the body where nerves cause pain to a specific organ or body region. Nerve blocks cause the temporary interruption of impulse conduction in peripheral nerves or nerve trunks and may or may not contain a steroid, which can be used to treat pain. Various areas of pain require different types of nerve blocks that can be administered in numerous parts of the body with some of the most common blocks being sympathetic, peripheral, and occipital.

Sacroiliac and facet joint interventions, epidural steroid injections, and trigger point injections are addressed in other policies.

C. Definitions

- **Acute Pain** – Pain that lasts less than 4 weeks.
- **Ambulatory Surgery** – Surgery performed in a hospital-based or freestanding ambulatory surgery center (ASC) with patient discharge the same day.
- **Chronic Pain** – Pain lasting more than 3 months, which is considered beyond normal healing time.
- **Conservative Therapy** – A multimodality plan of care including both active and inactive conservative therapies.
    - **Active Conservative Therapies** – Actions or activities that strengthen muscle groups and target key spinal structures, including physical therapy, occupational therapy, and/or a physician-supervised home exercise program (HEP).
        - **HEP** – A 6-week program requiring an exercise prescription, and/or plan and a follow-up documented in the medical record after completion, or documentation of the inability to complete due to a stated physical reason (ie, increased pain, inability to physically perform exercise). Patient inconvenience and/or noncompliance without explanation does not constitute an inability to complete.
    - **Inactive Conservative Therapies** – Passive activities that aid in treating symptoms associated with pain, including rest, ice, heat, medical devices, TENS unit, and/or pharmacotherapy (prescription or over the counter [non-steroidal anti-inflammatory drugs, acetaminophen]).
        - **Transcutaneous Electrical Nerve Stimulator (TENS)** – A device that utilizes electrical current directed through electrodes placed on the surface of the skin to decrease the patient's perception of pain by inhibiting the transmission of afferent pain nerve impulses and/or stimulate the release of endorphins. Use, frequency, duration, and start dates must be documented in the medical record.
- **Emergent** – Medically necessary care, which is immediately needed to preserve life, prevent serious impairment to bodily functions, organs, or parts, or prevent placing the physical or mental health of a patient in serious jeopardy.
- **Low-Risk Procedure** – Procedures associated with minimal physiologic effect and excludes any intrathoracic, intra-abdominal, vascular, or orthopedic procedures.

- **Sub-Acute Pain** – Pain lasting between 4 to 12 weeks.

D. Policy

I. CareSource considers peripheral nerve blocks (PNB), single injection, medically necessary when appropriate documentation for the treatment of acute pain or chronic pain are included, only as part of an active component of a comprehensive pain management program. CareSource uses MCG Health guidelines to address criteria for specific nerve blocks. Documentation must include indications that **ALL** the following criteria are met:

A. PNB is performed as an ambulatory or outpatient procedure that (1) is not treating an emergent condition, (2) is a low-risk procedure, and (3) requires no inpatient care for a preoperative disease or condition (eg, altered mental status, hypotension, hypoxemia, tachycardia).

B. Acute, sub-acute or chronic, neuropathic or radicular pain, as indicated by **ONE or more** of the following:

1. cancer-related pain
2. complex regional pain syndrome (CRPS)
3. peripheral neuropathy with pain that limits activities of daily living, excluding diabetic neuropathy
4. peripheral vascular disease with rest pain
5. acute herpes zoster of face or neck and prevention of postherpetic neuralgia
6. pancreatic pain, pelvic pain, or abdominal pain related to malignancy
7. chronic, relapsing pancreatitis

C. Symptoms poorly controlled by maximum medical therapy or intolerable side effects to such therapy.

D. Failure of non-invasive treatment(s) (eg, non-steroidal anti-inflammatory drugs (NSAIDs), exercise, physical therapy, spinal manipulation therapy).

E. No coagulopathy or thrombocytopenia.

F. No infection at or underlying the injection site.

II. Acute or Sub-Acute Pain

PNB may provide means of analgesia for acute pain in the following (not an all-inclusive list):

A. Patients at risk of respiratory depression related to systemic or neuraxial opioids (eg, obstructive sleep apnea, severe obesity, underlying pulmonary disease, advanced age).

B. Patients with another indication to minimize opioid use (eg, chronic opioid use, intolerance to opioids).

C. Patients with acute, severe pain poorly managed with systemic medication.

D. Patients who cannot tolerate chiropractic or other physical and/or manipulative therapies.

III. Chronic Pain

CareSource considers PNB, single injection, medically necessary when appropriate documentation for the treatment of chronic pain is included, only as part of an active

component of a comprehensive pain management program when there has been a failure of conservative therapy, as evidenced by **ALL** the following:

1. Documentation in the medical record of at least 6 weeks of active conservative therapy within the past 6 months OR inability to complete active conservative therapy due to contraindication, increased pain, or intolerance.
2. Documentation in the medical record of at least 6 weeks inactive conservative therapy within the past 6 months.

Insufficient evidence supports the following uses of PNB for **chronic** pain and is not considered medically necessary:

1. genicular nerve or branches for chronic knee pain
2. cluneal nerve injections or blocks for chronic low back pain
3. pudendal blocks for chronic pelvic pain conditions

IV. Radiofrequency Ablation (RFA) or Neurotomy
Radiofrequency ablation and/or neurotomy are considered experimental and investigational, or unproven for any indication, including but not limited to the treatment of acute or chronic pain due to insufficient evidence of efficacy in the peer reviewed literature.

V. Limitations and Exclusions
   A. A member can receive a maximum of 6 injections in a rolling 12 month period.
   B. Up to 2 anatomic sites (eg, specific nerve, plexus, or branch as defined by CPT code description) can be injected at any one session.
   C. Nerve blocks used as part of a surgical procedure or other medical procedure are not separately reimbursable but an inclusive component of that procedure. These injections will not be compensated separately or unbundled for coverage.
   D. Any procedure submitted for payment with an incorrect CPT code or description will be denied. It is the responsibility of the submitting provider to submit the most accurate and appropriate CPT/HCPCS code(s) for the product or service that is being provided. If requesting a block to a specific part of the body, coding to the highest level of specificity should be used.
   E. Exclusions
      1. Treatment of peripheral neuropathy due to diabetes.
      2. Use of nerve blocks with or without use of electrostimulation for treatment of multiple neuropathies or peripheral neuropathies caused by underlying systemic diseases. Medical management using systemic medications is clinically indicated for the treatment of these conditions.

E. Conditions of Coverage

Interventional procedures for the management of pain unresponsive to conservative treatment should be provided only by healthcare providers within their scope of practice who are qualified to deliver these health services.

F. Related Policies/Rules

Experimental or Investigational Item or Service

Facet Joint Interventions
Sacroiliac Joint Procedures
Trigger Point Injections

G. Review/Revision History

	DATE	ACTION
Date Issued	02/15/2023	Approved at Committee.
Date Revised	02/28/2024 02/26/2025 01/28/2026	Annual review. Updated references. Approved at Committee. Annual review, references updated. Approved at Committee. Annual review, approved at Committee.
Date Effective	11/01/2026	
Date Archived		

H. References

1. Ailani J, Burch RC, Robbins MS; American Headache Society. The American Headache Society consensus statement: update on integrating new migraine treatments into clinical practice. *Headache*. 2021;61(7):1021-1039. doi:10.1111/head.14153
2. Allen SM, Mookadam F, Cha SS, et al. Greater occipital nerve block for acute treatment of migraine headache: a large retrospective cohort study. *J Am Board Fam Med*. 2018;31(2):211-218. doi:10.3122/jabfm.2018.02.170188
3. American Headache Society. AHS consensus statement: The American Headache Society position statement on integrating new migraine treatments into clinical practice. *Headache*. 2019;59(1):1-18. doi:10.1111/head.13456
4. Antolak S, Antolak C, Lendway L. Measuring the quality of pudendal nerve perineural injections. *Pain Physician*. 2016;19:299-306. Accessed January 13, 2026. www.pubmed.ncbi.nlm.nih.gov
5. Caponnetto V, Ornello R, Frattale I, et al. Efficacy and safety of greater occipital nerve block for the treatment of cervicogenic headache: a systematic review. *Expert Rev Neurotherapeutics*. 2021; 21(5):591-597. doi:10.1080/14737175.2021.1903320
6. Chang A, Dua A, Singh K, et al. Peripheral nerve blocks. *StatPearls*. StatPearls Publishing; 2025. Accessed January 13, 2026. www.ncbi.nlm.nih.gov
7. Chou R. Subacute and chronic low back pain: nonsurgical interventional treatment. UpToDate. Updated April 29, 2025. Accessed January 12, 2026. www.uptodate.com
8. Dowell D, Ragan KR, Jones CM, et al. CDC clinical practice guideline for prescribing opioids for pain. *MMWR Recomm Rep.* 2022;71(3):1-95. doi:10.15585/mmwr.rr7103a1
9. Evidence Analysis Research Brief: Genitofemoral Nerve Block or Ablation for Treatment of Groin Pain. Hayes; 2024. Accessed January 13, 2026. www.evidence.hayesinc.com
10. Evidence Analysis Research Brief: Local Injection Therapy for Cervicogenic Headache and Occipital Neuralgia. Hayes; 2023. Accessed January 13, 2026, 2025. www.evidence.hayesinc.com
11. Evidence Analysis Research Brief: Peripheral Nerve Stimulation for the Treatment of Superior Cluneal Neuralgia. Hayes; 2024. Accessed January 13, 2026. www.evidence.hayesinc.com

12. Evidence Analysis Research Brief: Radiofrequency Ablation of Cluneal Nerve for Treatment of Chronic Low Back Pain. Hayes; 2023. Accessed January 13, 2026.
13. Evolving Evidence Review: Middle Cluneal Nerve Block for Treatment of Low Back Pain. Hayes; 2022. Reviewed February 7, 2025. Accessed January 13, 2026. www.evidence.hayesinc.com
14. Evolving Evidence Review: Percutaneous Conventional Radiofrequency Ablation of Medial Branch Nerve(s) for Treatment of Thoracic Spinal Pain. Hayes; 2025. Accessed January 13, 2026. www.evidence.hayesinc.com
15. Evolving Evidence Review: Pulsed Radiofrequency for the Treatment of Pudendal Neuralgia. Hayes; 2024. Reviewed November 13, 2025. Accessed January 13, 2026. www.evidence.hayesinc.com
16. Evolving Evidence Review: Superior Cluneal Nerve Block for Treatment of Low Back Pain. Hayes; 2021. Reviewed December 18, 2024. Accessed January 13, 2026. www.evidence.hayesinc.com
17. Frank FT, Sawsan A. Chronic pelvic pain in adult females: treatment. UpToDate. Updated August 16, 2024. Accessed June 23, 2025. www.uptodate.com
18. Garza I. Occipital neuralgia. UpToDate. Updated March 3, 2025. Accessed January 13, 2026. www.uptodate.com
19. Garza I, Schwedt TJ. Chronic migraine. UpToDate. Updated October 3, 2024. Accessed January 13, 2026. www.uptodate.com
20. Gautam S, Gupta N, Khuba S, et al. Evaluation of the efficacy of superior cluneal nerve block in low back pain: a prospective observational study. *J Bodyw Mov Ther*. 2022;30:221-225. doi:10.1016/j.jbmt.2022.03.001
21. *Headaches in Over 12s: Diagnosis and Management*. National Institute for Excellence; 2021. NICE Guideline No 150. Updated June 3, 2025. Accessed January 13, 2026. www.nice.org
22. Health Technology Assessment: Cooled or Pulsed Radiofrequency for Chronic Low Back Pain Arising From the Sacroiliac Joint. Hayes; 2022. Reviewed December 10, 2024. Accessed January 13, 2026. www.evidence.hayesinc.com
23. Health Technology Assessment: Genicular Nerve Block for the Treatment of Knee Osteoarthritis. Hayes; 2023. Reviewed December 4, 2025. Accessed January 13, 2026. www.evidence.hayesinc.com
24. Health Technology Assessment: Greater Occipital Nerve Blocks for Treatment of Migraine. Hayes; 2019. Reviewed October 10, 2022. Accessed January 13, 2026. www.evidence.hayesinc.com
25. Health Technology Assessment: Peripheral Nerve Field Stimulation for Treatment of Chronic Low Back Pain. Hayes; 2021. Reviewed April 17, 2024. Accessed January 13, 2026. www.evidence.hayesinc.com
26. Health Technology Assessment: Pulsed Radiofrequency for Treatment of Chronic Shoulder Pain. Hayes; 2022. Reviewed September 16, 2025. Accessed January 13, 2026. www.evidence.hayesinc.com
27. Health Technology Assessment: Radiofrequency Nerve Ablation for the Management of Osteoarthritis of the Knee. Hayes; 2020. Reviewed December 28, 2023. Accessed January 13, 2026. www.evidence.hayesinc.com
28. Hui J, Seko K, Shrikhande G, et al. A novel, nonopiod-based treatment approach to men with urologic chronic pelvic pain syndrome using ultrasound-guided nerve

hydrodissection and pelvic floor musculature trigger point injections. *Neurourol Urodyn*. 2020;39(2):658-664. doi:10.1002/nau.24242
29. Inan L, Inan N, Unal-Artik H, et al. Greater occipital nerve block in migraine prophylaxis: narrative review. *Cephalalgia*. 2019;39:908-920. doi:10.1177/0333102418821669
30. Isu T, Kim K, Morimoto D, et al. Superior and middle cluneal nerve entrapment as a cause of low back pain. *Neurospine*. 2018;15(1):25-32. doi:10.14245/ns.1836024.012
31. Jeng C, Rosenblatt M. Overview of peripheral nerve blocks. UpToDate. Updated July 30, 2025. Accessed January 13, 2026. www.uptodate.com
32. Matsumoto J, Isu T, Kim K, et al. Middle cluneal nerve entrapment mimics sacroiliac joint pain. *Acta Neurochir (Wien)*. 2019;161(4):657-661. doi:10.1007/s00701-019-03861-0
33. Mustafa A, Brooks B, Leishear K, et al. A novel treatment approach for women with chronic pelvic pain syndrome leading to increased pelvic functionality. *J Womens Health Gyn*. 2020;7:1-10. doi:10.17303/jwhg.2020.7.402
34. Nielsen TD, Moriggl B, Barckman J, et al. Randomized trial of ultrasound-guided superior cluneal nerve block. *Reg Anesth Pain Med*. 2019;44:772-780. doi:10.1136/rapm-2018-100174
35. Ornello R, Lambru G, Caponnetto V, et al. Efficacy and safety of greater occipital nerve block for the treatment of cluster headache: a systematic review and meta-analysis. *Expert Rev Neurotherapeutics*. 2020;20(11):1157-1167. doi:10.1080/14737175.2020.1809379
36. Plavnik K, Tenaglia A, Hill C, et al. A novel, non-opioid treatment for chronic pelvic pain in women with previously treated endometriosis utilizing pelvic-floor musculature trigger-point injections and peripheral nerve hydrodissection. *PM R*. 2020;12(7):655-662. doi:10.1002/pmrj.12258
37. Practice guidelines for chronic pain management: an updated report by the American Society of Anesthesiologists Task Force on chronic pain management and the American Society of Regional Anesthesia and Pain Medicine. *Anesthesiology*. 2010;112(4):810-833. doi:10.1097/ALN.0b013e3181c43103
38. Shauly O, Gould DJ, Sahai-Srivastava S, et al. Greater occipital nerve block for the treatment of chronic migraine headaches: a systematic review and meta-analysis. *Plast Reconstr Surg*. 2019;144(4):943-952. doi:10.1097/PRS.0000006059
39. Tu FF, As-Sanie S. Chronic pelvic pain in adult females: evaluation. UpToDate. Updated September 11, 2025. Accessed January 13, 2026. www.uptodate.com
40. Watson JC. Cervicogenic headache. UpToDate. Updated September 9, 2025. Accessed January 13, 2026. www.uptodate.com
41. Wray JK, Dixon B, Przkora R. Radiofrequency ablation. *StatPearls*. StatPearls Publishing; 2025. Accessed January 13, 2026. www.ncbi.nlm.nih.gov